STAT Plus: Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics
APSTOCK
Investor expectations are running high for Mirati Therapeutics, whose upcoming trial readout may be an important stock-moving catalyst.
No hay comentarios:
Publicar un comentario